Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 160 Cr.
- Current Price ₹ 101
- High / Low ₹ 132 / 85.2
- Stock P/E
- Book Value ₹ 87.8
- Dividend Yield 0.00 %
- ROCE 6.25 %
- ROE 0.84 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.15 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 6.71% over past five years.
- Company has a low return on equity of 11.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
153 | 124 | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 357 | |
139 | 129 | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 352 | |
Operating Profit | 14 | -4 | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 6 |
OPM % | 9% | -4% | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 2% |
1 | 2 | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | |
Interest | 10 | 10 | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 13 |
Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 14 |
Profit before tax | 1 | -17 | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -21 |
Tax % | 44% | 30% | 22% | -2% | 33% | 29% | 32% | -40% | -32% | 29% | 29% | 43% | |
1 | -12 | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -17 | |
EPS in Rs | 0.48 | -8.95 | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -10.73 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 7% |
3 Years: | 10% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | -42% |
3 Years: | -46% |
TTM: | -238% |
Stock Price CAGR | |
---|---|
10 Years: | 36% |
5 Years: | 13% |
3 Years: | -11% |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 8% |
3 Years: | 12% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 25 | 13 | 10 | 16 | 39 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 123 |
61 | 73 | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 89 | |
23 | 16 | 25 | 63 | 47 | 38 | 54 | 50 | 75 | 64 | 90 | 119 | 159 | |
Total Liabilities | 122 | 115 | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 360 | 387 |
57 | 55 | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 151 | |
CWIP | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
65 | 59 | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 208 | 236 | |
Total Assets | 122 | 115 | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 360 | 387 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | -1 | 7 | 14 | 22 | 43 | 25 | 22 | 31 | 28 | 26 | 40 | |
-6 | -2 | -2 | -4 | -11 | -39 | -16 | -9 | -7 | -31 | -27 | -22 | |
-0 | 2 | -5 | -10 | -11 | -3 | -9 | -11 | -23 | 3 | 3 | -17 | |
Net Cash Flow | 0 | -1 | 0 | 1 | -0 | 0 | -0 | 1 | 0 | -1 | 1 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 21 | 70 | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 |
Inventory Days | 165 | 112 | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 |
Days Payable | 43 | 39 | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 141 |
Cash Conversion Cycle | 143 | 144 | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 104 |
Working Capital Days | 96 | 125 | 122 | 79 | 76 | 70 | 99 | 102 | 66 | 75 | 84 | 93 |
ROCE % | 12% | -7% | 6% | 16% | 30% | 32% | 25% | 2% | 11% | 27% | 18% | 6% |
Documents
Announcements
- Reg 40(10) Certificate Of The Company For The Period Ended March 31 2024 20h
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 19 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Compliances certificate under Reg 74(5) for the quarter ended March 31 2024.
- Closure of Trading Window 30 Mar
- Board Meeting Outcome for The Board At Its Meeting Held On 15.03.2024 Considered And Approved The Scheme Of Merger By Absorption. 16 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations